VahatiCor, a T45 Labs portfolio company, develops innovative medical technology solutions for patients with Coronary Microvascular Dysfunction (CMD), a debilitating condition affecting millions of people who experience chest pain despite having no blockages in their major coronary arteries. The A-FLUX Reducer System® introduces a new therapeutic pathway for patients affected by coronary microvascular dysfunction (CMD), a condition that can cause chest pressure, heaviness, and discomfort. Through this advancement, VahatiCor is helping broaden access to care for individuals who have long faced limited treatment alternatives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/18/25 | $23,000,000 | Series B |
Intuitive Ventures S3 Ventures  | undisclosed |
